Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey

• Published in: BMC cancer Vol. 12; no. 1; p. 152
• Main Authors: Kodama, Yuko, Morozumi, Ryoko, Matsumura, Tomoko, Kishi, Yukiko, Murashige, Naoko, Tanaka, Yuji, Takita, Morihito, Hatanaka, Nobuyo, Kusumi, Eiji, Kami, Masahiro, Matsui, Akihiko
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 24.04.2012; BioMed Central; BMC
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anticancer drug; Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Benzamides - therapeutic use; Cancer patients; Care and treatment; Economic aspects; Economic recession; Female; Foreign exchange; Health Care Costs - statistics & numerical data; Health insurance; Hematology; Households; Humans; Imatinib Mesylate; Japan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - economics; Male; Medical research; Medicine, Experimental; Middle Aged; Myelocytic leukemia; Nonlymphoid leukemia; Piperazines - therapeutic use; Prices and rates; Pyrimidines - therapeutic use; Quality of life; Recessions; Retrospective Studies; Socioeconomic Factors; Studies; Surveys; Surveys and Questionnaires; Young Adult; Japan
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/1471-2407-12-152

The financial burden of medical expenses has been increasing for cancer patients. We investigated the relationship between household income and financial burden among patients with chronic myelogenous leukaemia (CML) who have been treated with imatinib. A questionnaire was distributed to 1200 patients between May and August 2009. We retrospectively surveyed their household incomes, out-of-pocket medical expenses, final co-payments after refunds, and the perceived financial burden of their medical expenses in 2000, 2005 and 2008. A total of 577 patients completed the questionnaire. Their median age was 61 years (range, 15-94). A financial burden was felt by 41.2 % (28 of 68) of the patients treated with imatinib in 2000, 70.8 % (201 of 284) in 2005, and 75.8 % (400 of 528) in 2008. Overall, 182 patients (31.7 %) considered its discontinuation because of the financial burden and 15 (2.6 %) temporarily stopped their imatinib prescription. In 2000, 2005 and 2008, the patients' median annual household incomes were 49,615 US Dollars (USD), 38,510 USD and 36,731 USD, respectively, with an average currency exchange rate of 104 Yen/USD in 2008. Their median annual out-of-pocket expenses were 11,548, 12,067 and 11,538 USD and their median final annual co-payments were 4,375, 4,327 and 3,558 USD, respectively. Older patients (OR = 0.96, 95 % CI: 0.95-0.98, p ≪ 0.0001 for 1-year increments), and patients with higher household incomes (OR = 0.92, 95 % CI: 0.85-0.99, p = 0.03 for 10,000 USD-increments) were less likely to have considered discontinuing their imatinib treatment. Conversely, patients with higher annual final co-payments (OR = 2.21, 95 % CI: 1.28-4.28, p = 0.004 for 10,000 USD-increments) were more likely to have considered discontinuing their imatinib treatment. The proportion of CML patients who sensed a financial burden increased between 2000 and 2008. During this period, their annual incomes fell by 13,000 USD, although their medical expenses did not change. Financial support for patients being treated with expensive drugs remains a major problem in Japan.